(WO/1991/007175) USE OF OPTICALLY PURE S(-) ATENOLOL FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS
- Biblio. Data
- Description
- Claims
- National Phase
- Notices
- Documents
| Latest bibliographic data on file with the International Bureau
| ||||||||||||
| ||||||||||||
| IPC: | A61K 31/165 (2006.01) | |||||||||||
| Applicant: | SEPRACOR, INC. [US/US]; 33 Locke Drive, Marlborough, MA 01752 (US). | |||||||||||
| Inventors: | BARBERICH, Timothy, J.; (US). BRATZLER, Robert, L.; (US). YOUNG, James, W.; (US). LOUIS, William, J.; (AU). | |||||||||||
| Agents: | GRANAHAN, Patricia et al.; Hamilton, Brook, Smith & Reynolds, Two Militia Drive, Lexington, MA 02173 (US). BROOK, David, E.; Hamilton, Brook, Smith & Reynolds, Two Militia Drive, Lexington, MA 02173 (US). | |||||||||||
| Priority Data: |
| |||||||||||
| Title: | USE OF OPTICALLY PURE S(-) ATENOLOL FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS | |||||||||||
| Abstract: | Optically pure S(-) atenolol, which is substantially free of the R(+) enantiomer, is a potent beta-blocker for controlling heartbeat, relieving the symptoms of angina pectoris and reducing blood pressure in individuals. A method is disclosed utilizing the optically pure S(-) enantiomer of atenolol for treating cardiovascular disorders while reducing undesirable side effects associated with beta-blockers. | |||||||||||
| Designated States: |
AU, CA, JP. European Patent Office (EPO) (AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE). | |||||||||||
| Publication Language: | English (EN) |
| Filing Language: | English (EN) |
